title: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
abstract: Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
authors.affiliation: Interdisciplinary Phase I/II Unit of the University of Würzburg, Klinikstrasse 6-8, 97070 Würzburg, Germany.
authors.forename: Ralf
authors.initials: R
authors.lastname: Bargou
authors.forename: Eugen
authors.initials: E
authors.lastname: Leo
authors.forename: Gerhard
authors.initials: G
authors.lastname: Zugmaier
authors.forename: Matthias
authors.initials: M
authors.lastname: Klinger
authors.forename: Mariele
authors.initials: M
authors.lastname: Goebeler
authors.forename: Stefan
authors.initials: S
authors.lastname: Knop
authors.forename: Richard
authors.initials: R
authors.lastname: Noppeney
authors.forename: Andreas
authors.initials: A
authors.lastname: Viardot
authors.forename: Georg
authors.initials: G
authors.lastname: Hess
authors.forename: Martin
authors.initials: M
authors.lastname: Schuler
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.forename: Christian
authors.initials: C
authors.lastname: Brandl
authors.forename: Andreas
authors.initials: A
authors.lastname: Wolf
authors.forename: Petra
authors.initials: P
authors.lastname: Kirchinger
authors.forename: Petra
authors.initials: P
authors.lastname: Klappers
authors.forename: Margit
authors.initials: M
authors.lastname: Schmidt
authors.forename: Gert
authors.initials: G
authors.lastname: Riethmüller
authors.forename: Carsten
authors.initials: C
authors.lastname: Reinhardt
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Baeuerle
authors.forename: Peter
authors.initials: P
authors.lastname: Kufer
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000276:immunology; D018655:Lymphocyte Count; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000276:immunology; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab